ICUS Weekly News Monitor 10-13-2017

ICUS -- International Contrast Ultrasound Society

Lose Weight While You Sleep? Maybe Soon, According to ICUS Conference Study

Media release

October 06, 2017

CHICAGO--(BUSINESS WIRE)--Obesity can be treated with an innovative gene therapy that produces weight loss and reduces fat according to a new study described today at the 32nd annual Advances in Ultrasound conference in Chicago.

Dr. Paul Grayburn of the Baylor University Medical Center, Dallas, TX focused on a brown antipose tissue (BAT) common in hibernating animals like bears and also in children that increases energy expenditure. In Dr. Grayburn’s animal study, a protein specific to this brown antipose tissue was uncoupled to improve metabolism.

“We were able to deliver a gene ‘cocktail’ via tiny gas-filled microbubbles into skeletal muscles that lead to increased fat and glucose oxidation and weight loss,” Grayburn said.

In the study finding, the same brown antipose tissue that increases energy production in hibernating bears was activated in fatty rats and led to decreased food intake, weight loss, and reduced fat.

More than one-third (36.5%) of U.S. adults have obesity according to the Centers for Disease Control and Prevention. This promising, minimally-invasive therapy is easier and less expensive than gastric bypass surgery. The average cost of gastric bypass surgery in the US is $23,000.

In a second study at the same International Contrast Ultrasound Society (ICUS) Chicago conference, Dr. Pintong Huang used gas-filled microbubbles to deliver gene therapy in non-human primates with diabetes. His results showed the gene therapy stimulated normal glucose and insulin levels that were sustained for three to six months. Professor Huang is Chair of Ultrasonography of the Second Affiliated Hospital of Zhejiang University School of Medicine in Hangzhou, China.

Prof. Huang concluded that the results require additional larger studies which if successful show promise for human patients with diabetes.


ICUS -- International Contrast Ultrasound Society

Cheaper Way to Detect Liver Cancer Without Harmful Radiation Imaging, According to ICUS Conference Study

Media release

October 06, 2017

CHICAGO--(BUSINESS WIRE)--Doctors can effectively detect liver cancer with ultrasound and tiny microbubbles -- and without radiation, expensive MRI equipment or biopsies, according to a study announced today at the International Contrast Ultrasound Society (ICUS) 32nd Annual Conference in Chicago.

The imaging technique, known as contrast-enhanced ultrasound (CEUS), "is an exciting option because it provides a more cost effective and less invasive way for accurately characterizing the tumor," said Dr. Stephanie Wilson, a professor of radiology at the University of Calgary and study author.

The study of over 200 patients at risk for hepatocellular carcinoma, the most common liver cancer and the second leading cause of cancer deaths worldwide, found that CEUS imaging using the microbubbles allowed for the correct diagnosis with 97% accuracy.

CEUS uses liquid suspensions of tiny gas microbubbles to improve the clarity and reliability of an ultrasound image. The microbubbles are smaller than red blood cells and, when they are injected into a patient's arm vein, they flow through the microcirculation and reflect ultrasound signals, improving the accuracy of diagnostic ultrasound exams. The microbubbles are expelled from the body within minutes.

Dr. Steven Feinstein, a professor of medicine at Rush University in Chicago, said the study validates the vast benefits of using microbubble ultrasound contrast agents as a safe, convenient and effective diagnostic imaging tool. "The findings are extremely exciting and demonstrate that CEUS imaging improves patient care without exposing individuals to tissue diagnosis or ionizing radiation,” Feinstein added.

Dr. Wilson’s study utilized the Liver Imaging Reporting and Data System (LI-RADS), a tool radiologists use to classify liver tumors using CT, MR and CEUS imaging in patients with suspected liver cancer. Additional prospective studies are expected according to Dr. Yuko Kono, a professor of Hepatology and Gastroenterology at the University of California San Diego and a leader in the CEUS imaging field.

ICUS Weekly News Monitor 9-29-17

European Society of Cardiology

European Heart Journal - Cardiovascular Imaging(2017) 0, 1-33

Doi: 10.1093/ehjci/jex182

Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017

Authors:  Roxy Senior1*, Harald Becher2, Mark Monaghan3, Luciano Agati4, Jose Zamorano5, Jean Louis Vanoverschelde6, Petros Nihoyannopoulos7, Thor Edvardsen8, and Patrizio Lancellotti9

1Department of Cardiology, Royal Brompton Hospital, Imperial College, Sydney Street, London SW3 6NP, UK; 2Alberta Heart Institute, Edmonton, Canada; 3King’s College Hospital, London, UK; 4La Sapienza University, Rome, Italy; 5CIBERCV, University Hospital Ramon y Cajal, Madrid, Spain; 6Cliniques Universitaires St-Luc, Universite´ Catholique de Louvain, Brussels, Belgium; 7Hammersmith Hospital, Imperial College, London, UK; 8Oslo University Hospital and University of Oslo, Norway; and 9University of Liege Hospital, GIGA Cardiovascular Science, Heart Valve Clinic, Imaging Cardiology, Liege, Belgium

September 30, 2017


Page 10: Contrast 2D echocardiography should be considered irrespective of image quality when clinical management depends on accurate measurements of LVEF such as monitoring of patients treated withcardiotoxic drugs and when implantation of ICD or CRT devices are considered (Class IIa, Level B).

It has been shown that contrast echocardiography improved confidence of the interpretation of regional LV wall motion and increased the inter-observer agreement from 80% (non-contrast tissue harmonic imaging) to 95% (2D contrast echocardiography) in intensive care unit patients.

They found an increased reproducibility of wall motion score index using contrast 2D echocardiography and that 55% of the patients were reclassified with motion abnormalities by contrast analysis. In patients 7–10 days after acute MI assessment of LV ESV and EF by contrast echocardiography showed incremental prognostic value for predicting hard events beyond clinical and non-contrast determined LV function.


European Society of Cardiology

European Heart Journal - Acute Cardiovascular Care

DOI: 10.1177/2048872617728559;

Therapeutic application of contrast ultrasound in ST elevation myocardial infarction: Role in coronary thrombosis and microvascular obstruction

Authors:  Jeroen Slikkerveer1,2, Lynda JM Juffermans1,2,3, Niels van Royen1,2, Yolande Appelman1,2, Thomas R Porter4 and Otto Kamp1,2

1 Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands; 2 Institute of Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands; 3 Department of Physiology, VU University Medical Center, Amsterdam, The Netherlands, 4University of Nebraska Medical Center, Omaha, Nebraska, USA

Corresponding author:  Jeroen Slikkerveer, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;  Email: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

September 30, 2017


In the past few decades, cardiac ultrasound has become a widely available, easy-to-use diagnostic tool in many scenarios in acute cardiac care. The introduction of microbubbles extended its diagnostic value. Not long thereafter, several investigators explored the therapeutic potential of contrast ultrasound on thrombus dissolution. Despite large improvements in therapeutic options, acute ST elevation myocardial infarction remains one of the main causes of mortality and morbidity in the western world. The therapeutic effect of contrast ultrasound on thrombus dissolution might prove to be a new, effective treatment strategy in this group of patients. With the recent publication of human studies scrutinising the therapeutic options of ultrasound and microbubbles in ST elevation myocardial infarction, we have entered a new stage in this area of research. This therapeutic effect is based on biochemical effects both at macrovascular and microvascular levels, of which the exact working mechanisms remain to be elucidated in full. This review will give an up-to-date summary of our current knowledge of the therapeutic effects of contrast ultrasound and its potential application in the field of ST elevation myocardial infarction, along with its future developments.


Health Imaging

Microbubble ultrasound, perfusion software combine to check ablation of liver lesions

By Dave Pearson

September 26, 2017

Following percutaneous interventions for malignant liver lesions, patients are ably assessed with a combination of contrast-enhanced ultrasound (CEUS) and perfusion-imaging software, according to the authors of a study published online September 25 in Ultraschall in der Medizin/European Journal of Ultrasound.

Radiologists and internists at the University of Regensburg in Germany reviewed the cases of 88 patients who had been treated with percutaneous ablation of 165 malignant liver lesions (108 hepatocellular carcinomas and 57 metastases).

Post-treatment, the patients were injected with sulfur hexafluoride microbubbles and imaged with ultrasound.

They were again assessed up to six months later, this time with contrast-enhanced CT or MRI.

Using commercially available perfusion software (Bracco’s VueBox), the researchers found “significant differences in all cases between the center compared to the margins for the main perfusion parameters,” lead author Isabel Wiesinger, MD, and colleagues report.

Further, all parameters—peak, wash-in and wash-out ratios alongside type of lesion and method of ablation—were significantly different between lesions treated successfully vs. those with recurrence, they write.

“A combination of CEUS with perfusion imaging enables critical assessment of successful treatment after percutaneous interventional procedures for a malignant liver lesion,” the authors conclude.

ICUS Weekly News Monitor 8-18-17


CEUS: Basic Training for Novices 


Stephanie Wilson, MD – ICUS Co-President and Basic Training Education Chair; University of Calgary

Andrej Lyshchik, MD, PhD – ICUS Member; Thomas Jefferson University Hospital

Event information:

September 9, 2017 Hotel Sofitel Philadelphia

8am to 4.30pm; 120 S. 17th Street Philadelphia, PA | Map

Program Description:

Expert lectures, case demonstrations and hands-on instruction for CEUS novices. Sessions will provide practical skills needed to implement a successful CEUS program – including how to determine optimal settings, inject contrast agents, and correctly interpret CEUS images.


CEUS: What, why and when?

Microbubble Contrast Agents: Safety, uses, cost effectiveness and handling.

Introduction to CEUS: Liver, kidney, other organ systems.

Getting started: From set-up to optimizing performance.

Case demonstrations: Featuring equipment of each sponsor.

Knobology: Break out rooms with personalized opportunities to "touch and feel" all of the featured ultrasound systems and contrast agents, examine settings, etc.

Who Should Attend:

Physicians, technologists, sonographers, trainees and other allied health care professionals


$125 (Includes breakfast and lunch)

To register, visit:

Accommodations: Hotel Sofitel – (215) 569-8300; ask for ICUS Event discount rate $239/night

Book by Aug 25 to get special rate!

Conference Secretariat:   This email address is being protected from spambots. You need JavaScript enabled to view it.


About ICUS:

ICUS is the only international professional society that exclusively focuses on advancing the safe and appropriate use of CEUS to improve patient care. ICUS membership is free; to join, simply ICUS Basic Training is supported by our generous sponsors.


Meeting Program

8:00 AM – 8:05 AM. Opening Remarks.

Andrej Lyshchik, MD, PhD (TJUH)

8:05 AM – 8:35 AM. Microbubble contrast agents and their Imaging Techniques.

Andrej Lyshchik, MD, PhD (TJUH)

8:35 AM – 9:15 AM. Tips of the Trade: How to do excellent CEUS examinations.

Stephanie Wilson, MD (University of Calgary)

9:15 AM – 10:00 AM. CEUS of the Liver.

Stephanie Wilson, MD (University of Calgary)

10:00 AM – 10:15 AM. Liver Imaging Reporting and Data System (LI-RADS).

Yuko Kono, MD, PhD (UCSD)

10:15 AM – 10:45 AM. Break.

10:45 AM – 11:00 AM. Clinical integration of CEUS in liver patient management.

Yuko Kono, MD, PhD (UCSD)

11:00 AM – 11:30 AM. CEUS of the Kidneys.

Andrej Lyshchik, MD, PhD (TJUH)

11:30 AM – 12:00 PM. Pediatric applications of CEUS.

Judith Machnitz, MD (CHOP)

12:00 PM – 12:15 PM. Commonly Asked Questions

Yuko Kono, MD, PhD (UCSD)

12:15 PM – 2:00 PM. Lunch / MANUFACTURERS EXIBITS.

Participants have lunch and visit manufacturers in the exhibition room. Manufacturers will demonstrate their equipment used for contrast-enhanced ultrasound. No patient scanning will be permitted.

2:00 PM – 2:30 PM. Surgical, vascular and interventional applications of CEUS.

Andrej Lyshchik, MD, PhD (TJUH)

2:30 PM – 3:00 PM. Questions & Answers.


3:00 PM – 4:15 PM. Case-Based Review: our best cases to show the scope of CEUS and to test your skills at basic interpretation.

Stephanie Wilson, MD (University of Calgary), Andrej Lyshchik, MD, PhD (TJUH)

4:15 PM – 4:30 PM. Wrap-Up


ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:






Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News